Publications by authors named "D B Soria"

Article Synopsis
  • Monomeric cobalt complexes [Co(SDZ)phen] and [Co(SDZ)(bq)Cl] were synthesized, with SDZ acting as a bidentate ligand in both.
  • X-ray diffraction studies revealed different coordination environments: complex 1 has a CoN coordination sphere, while complex 2 has a CoNCl core with contributions from another ligand.
  • Both complexes exhibit slow magnetic relaxation under a dc field at low temperatures, with compound 2 showing long-range magnetic ordering due to spin-canted antiferromagnetism, supported by various magnetic measurements.
View Article and Find Full Text PDF

Individuals developing stroke have varying clinical characteristics, demographic, and biochemical profiles. This heterogeneity in phenotypic characteristics can impact on cardiovascular disease (CVD) morbidity and mortality outcomes. This study uses a novel clustering approach to stratify individuals with incident stroke into phenotypic clusters and evaluates the differential burden of recurrent stroke and other cardiovascular outcomes.

View Article and Find Full Text PDF

Background And Aims: To evaluate the effects of a high-fat diet during post-weaning growth on intermediate metabolism and retroperitoneal adipose tissue, in adult male rats exposed to adequate or deficient zinc intake during prenatal and postnatal life.

Methods And Results: Female Wistar rats were fed low- or control-zinc diets from pregnancy to offspring weaning. Male offspring born from control mothers were fed either control or high-fat, control-zinc diets for 60 days.

View Article and Find Full Text PDF

Heterogeneous catalytic hydrogenation is an interesting alternative to conventional methods that use inorganic hydrides. The hydrogenation of acetophenone under heterogeneous conditions with the supported catalysts based on Ni is the most useful due to its redox properties and lower cost. As is well-known, catalyst support can significantly affect catalyst performance.

View Article and Find Full Text PDF
Article Synopsis
  • Remdesivir (RDV) was the first FDA-approved antiviral for treating severe COVID-19 by inhibiting SARS-CoV-2 replication through targeting an essential protein (nsp12) in the virus.
  • In a study, 38.3% of patients showed no response to RDV treatment, with specific genetic mutations detected in non-responders, indicating possible pathways to RDV resistance.
  • The findings highlight the need for ongoing monitoring of genetic variations in the virus, especially among immunosuppressed patients, to inform treatment strategies and health surveillance efforts as RDV continues to be used.
View Article and Find Full Text PDF